

Daniel D Murray

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1677842/publications.pdf>

Version: 2024-02-01

22
papers

986
citations

686830

13
h-index

752256

20
g-index

26
all docs

26
docs citations

26
times ranked

2317
citing authors

#	ARTICLE	IF	CITATIONS
1	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	13.9	357
2	Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression. <i>Journal of Immunology</i> , 2012, 188, 6238-6246.	0.4	152
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	2.0	56
4	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet</i> , The, 2022, 399, 530-540.	6.3	48
5	Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. <i>RNA Biology</i> , 2011, 8, 1035-1046.	1.5	45
6	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0139981.	1.1	45
7	Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients. <i>Blood Advances</i> , 2020, 4, 5797-5809.	2.5	42
8	miRNAs and HIV: unforeseen determinants of host-pathogen interaction. <i>Immunological Reviews</i> , 2013, 254, 265-280.	2.8	37
9	Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals. <i>Scientific Reports</i> , 2017, 7, 10934.	1.6	36
10	The role of microRNAs in HIV-1 pathogenesis and therapy. <i>Aids</i> , 2012, 26, 1325-1334.	1.0	34
11	Sepsis: Personalized Medicine Utilizing "Omicron" Technologies? A Paradigm Shift?. <i>Healthcare (Switzerland)</i> , 2018, 6, 111.	1.0	20
12	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. <i>Journal of Infectious Diseases</i> , 2019, 220, 1325-1334.	1.9	18
13	Incidence Rates and Risk Factors of <i>Clostridioides difficile</i> Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz086.	0.4	17
14	Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance. <i>Journal of Clinical Medicine</i> , 2019, 8, 1163.	1.0	16
15	Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3). <i>Clinical Trials</i> , 2022, 19, 52-61.	0.7	16
16	The central role of the glutamate metabolism in long-term antiretroviral treated HIV-infected individuals with metabolic syndrome. <i>Aging</i> , 2021, 13, 22732-22751.	1.4	14
17	Integrative Lipidomics and Metabolomics for System-Level Understanding of the Metabolic Syndrome in Long-Term Treated HIV-Infected Individuals. <i>Frontiers in Immunology</i> , 2021, 12, 742736.	2.2	11
18	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. <i>American Journal of Hypertension</i> , 2020, 33, 43-52.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. <i>Journal of Infectious Diseases</i> , 2021, 224, 2053-2063.	1.9	6
20	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 72, 1141-1146.	2.9	2
21	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. <i>Aids</i> , 2021, 35, 783-789.	1.0	2
22	2569. The Gut Microbiome and Acute Graft vs. Host Disease Risk in Hematopoietic Stem Cell Transplantation Recipients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S892-S893.	0.4	0